Gastric Retained Gabapentin Dosage Form

  • US 20120289601A1
  • Filed: 07/27/2012
  • Published: 11/15/2012
  • Est. Priority Date: 10/25/2001
  • Status: Active Grant
First Claim
Patent Images

1. A dosage form, comprising:

  • a matrix comprising gabapentin, wherein upon ingestion of the dosage form by a human gabapentin is released from the matrix into the upper gastrointestinal tract over about 5-12 hours at a rate sufficient to achieve a lower maximum plasma concentration than that provided by an immediate release dosage form comprising an equal amount of gabapentin, and bioavailability of gabapentin is at least 80% of that provided by the immediate release dosage form comprising an equal amount of gabapentin as measured by the area under the plasma concentration-time curve, AUCinf.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×